242 related articles for article (PubMed ID: 30227844)
1. Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
Zhang R; Ma M; Lin XH; Liu HH; Chen J; Chen J; Gao DM; Cui JF; Ren ZG; Chen RX
BMC Cancer; 2018 Sep; 18(1):901. PubMed ID: 30227844
[TBL] [Abstract][Full Text] [Related]
2. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition.
Zhang R; Lin XH; Ma M; Chen J; Chen J; Gao DM; Cui JF; Chen RX
J Transl Med; 2018 Nov; 16(1):302. PubMed ID: 30400797
[TBL] [Abstract][Full Text] [Related]
3. Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Zhang R; Ma M; Dong G; Yao RR; Li JH; Zheng QD; Dong YY; Ma H; Gao DM; Cui JF; Ren ZG; Chen RX
Cancer Sci; 2017 Sep; 108(9):1778-1786. PubMed ID: 28699238
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
5. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma.
Yoshida S; Kornek M; Ikenaga N; Schmelzle M; Masuzaki R; Csizmadia E; Wu Y; Robson SC; Schuppan D
Hepatology; 2013 Nov; 58(5):1667-80. PubMed ID: 23729316
[TBL] [Abstract][Full Text] [Related]
6. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins.
Zhang N; Li H; Qin C; Ma D; Zhao Y; Zhu W; Wang L
J Cancer Res Clin Oncol; 2019 Apr; 145(4):895-907. PubMed ID: 30820716
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
Liu J; Liu Y; Meng L; Ji B; Yang D
Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
[No Abstract] [Full Text] [Related]
9. Activated hepatic stellate cells promote progression of post-heat residual hepatocellular carcinoma from autophagic survival to proliferation.
Zhang R; Lin XH; Liu HH; Ma M; Chen J; Chen J; Gao DM; Cui JF; Chen RX
Int J Hyperthermia; 2019; 36(1):253-263. PubMed ID: 30701994
[TBL] [Abstract][Full Text] [Related]
10. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
11. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
12. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
13. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
14. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling.
Zhang N; Wang L; Chai ZT; Zhu ZM; Zhu XD; Ma DN; Zhang QB; Zhao YM; Wang M; Ao JY; Ren ZG; Gao DM; Sun HC; Tang ZY
PLoS One; 2014; 9(12):e115949. PubMed ID: 25542041
[TBL] [Abstract][Full Text] [Related]
15. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways.
Dong S; Kong J; Kong F; Kong J; Gao J; Ke S; Wang S; Ding X; Sun W; Zheng L
J Transl Med; 2013 Oct; 11():273. PubMed ID: 24168056
[TBL] [Abstract][Full Text] [Related]
16. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
17. Platelet lysates in Hepatocellular Carcinoma patients after radiofrequency ablation facilitate tumor proliferation, invasion and vasculogenic mimicry.
Jia G; Kong J; Yao C; Wu S; Sun W
Int J Med Sci; 2020; 17(14):2104-2112. PubMed ID: 32922171
[No Abstract] [Full Text] [Related]
18. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
19. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
20. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]